Transgene SA

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025

12 Jan 2026 12:00:00 بحسب Nasdaq GlobeNewswire

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

09 Jan 2026 02:00:00 بحسب Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

17 Dec 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets

26 Nov 2025 18:15:00 بحسب Nasdaq GlobeNewswire

Transgene Successfully Completes a Fundraising of c. €105 Million

26 Nov 2025 17:32:58 بحسب Nasdaq GlobeNewswire

Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris

25 Nov 2025 14:41:55 بحسب Nasdaq GlobeNewswire

Correction: Transgene launches a fundraising campaign for approximately 105 million euros

25 Nov 2025 13:15:54 بحسب Nasdaq GlobeNewswire

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

06 Nov 2025 02:30:00 بحسب Nasdaq GlobeNewswire

Transgene Provides Business and Financial Update for Q3 2025

04 Nov 2025 11:50:00 بحسب Nasdaq GlobeNewswire

New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse

04 Nov 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

20 Oct 2025 02:30:00 بحسب Nasdaq GlobeNewswire

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

13 Oct 2025 02:30:00 بحسب Nasdaq GlobeNewswire

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

03 Oct 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data  Randomization to be Completed in Phase II Part in Q4 2025

16 Sep 2025 11:45:00 بحسب Nasdaq GlobeNewswire

2025 Half-year financial information

16 Sep 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Availability of Transgene’s Half-Year Financial Report as of June 30, 2025

16 Sep 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025

28 Jul 2025 02:30:00 بحسب Nasdaq GlobeNewswire

Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director

09 Jul 2025 11:45:00 بحسب Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025

08 Jul 2025 12:00:00 بحسب Nasdaq GlobeNewswire

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

19 Jun 2025 02:00:00 بحسب Nasdaq GlobeNewswire